Articles from Corsera Health, Inc.

Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to initiate a Phase 1 clinical trial of COR-1004 in New Zealand. COR-1004 is a novel investigational subcutaneously administered RNAi medicine targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), which controls low-density lipoprotein cholesterol (LDL-C) levels in the blood. COR-1004 is the first of two components in the lead preventative medicine program at Corsera. A Phase 1 trial with COR-2003, targeting angiotensinogen (AGT), is anticipated in mid-2026. Corsera Health is advancing its first preventive RNAi medicine program designed to reduce the production of both PCSK9 and AGT - to lower LDL-C and blood pressure - as a single medicine given once a year.

Corsera Health, Inc. announced its launch today with a mission to extend healthspan through cardiovascular disease prediction and prevention. The company will shape the future of cardiovascular health by empowering individuals to understand and reduce their risk of atherosclerotic cardiovascular disease (ASCVD). With a preventive RNAi medicine expected to enter the clinic by the end of 2025, administered once-annually and priced to enable broad access, Corsera Health aims to prevent cumulative cardiovascular damage and support longer, healthier lives. The company has raised over $50 million to date from founders and insiders.